Skip to Content

David F. Sorensen

Managing Shareholder
P: 215.875.5705
F: 215.875.4604 Download vCard

David F. Sorensen is a managing shareholder, graduated from Duke University (A.B. 1983) and Yale Law School (J.D. 1989), and clerked for the Hon. Norma L. Shapiro (E.D. Pa.).   He concentrates his practice on antitrust and environmental class actions.

Mr. Sorensen's work with respect to mass torts is significant.  He helped try a class action property damage case, Cook v. Rockwell Corporation that resulted in a jury verdict of $554 million in February 2006, after a four-month trial, on behalf of thousands of property owners near the former Rocky Flats nuclear weapons plant located outside Denver, Colorado.  The jury verdict is the largest in Colorado history, and is the first time a jury has awarded damages to property owners living near one of the nation's nuclear weapons sites. In 2008, after extensive post-trial motions, the District Court entered a $926 million judgment for the plaintiffs. The jury verdict in the case was vacated on appeal in 2010. In 2015, on a second trip to the Tenth Circuit Court of Appeals, Plaintiffs secured a victory with the case being sent back to the district court.  On May 18, 2016, the parties announced they had reached a $375 million settlement.  For his work in this case, Mr. Sorensen was among the trial team named Trial Lawyer of the Year for 2009 by the Public Justice Foundation. He also has written and lectured about the case.  He has been designated a "Super Lawyer" by Philadelphia Magazine many years in a row.

Mr. Sorensen played a major role in the firm's representation of the State of Connecticut in State of Connecticut v. Philip Morris, Inc., et al., in which Connecticut recovered approximately $3.6 billion (excluding interest) from certain manufacturers of tobacco products.

Mr. Sorensen also has played a leading role in numerous antitrust cases representing direct purchasers of prescription drugs.  These cases have alleged that pharmaceutical manufacturers have wrongfully kept less expensive generic drugs off the market, in violation of the antitrust laws.  Many of these cases have resulted in substantial cash settlements, including In re ModafinilI Antitrust Litigation ($512 million); In re Prandin Direct Purchaser Antitrust Litigation ($19 million); In re Doryx Antitrust Litigation ($15 million); In re Skelaxin Antitrust Litigation ($73 million); In re Neurontin Antitrust Litigation ($190 million); In re Wellbutrin XL Antitrust Litigation ($37.50 million); In re Oxycontin Antitrust Litigation ($16 million); In re DDAVP Direct Purchaser Antitrust Litigation ($20.25 million); In re Nifedipine Antitrust Litigation ($35 million); In re Terazosin Hydrochloride Antitrust Litigation, MDL 1317 (S.D. Fla.) ($74.5 million); and In re Remeron Antitrust Litigation. ($75 million).

Prominent Judgments & Settlements